Last reviewed · How we verify
NCT03497936
Marketability of a Technology-based Intervention to Increase HPV Vaccination
NA trial testing Women's Stories in Human Papilloma Virus in 360 participants. Completed in 29 March 2021.
29 March 2021
Quick facts
| Lead sponsor | Real Prevention, LLC |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 360 |
| Start date | 1 May 2018 |
| Primary completion | 29 March 2021 |
| Estimated completion | 29 March 2021 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Women's Stories
Conditions studied
- Human Papilloma Virus — all drugs for Human Papilloma Virus →
Sponsor
Real Prevention, LLC
Who can join
Adults 18 to 26, female only, with Human Papilloma Virus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal of this SBIR Phase II project is to reduce cancer rates by marketing a brief, easily implemented technology-based intervention that increases human papillomavirus (HPV) vaccination among Planned Parenthood and other clients. The intervention's innovative technology allows for the investigators' narrative videos to be presented along will reminder texts. It will be evaluated for use in waiting rooms and promises to overcome vaccination barriers among high risk but underserved low SES and minority populations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03497936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Papilloma Virus
Currently open trials in the same condition.
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06414057 — HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks · recruiting
- NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Phase 1 · recruiting
- NCT06598176 — Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples · NA · recruiting
- NCT05996783 — Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial · NA · active not recruiting
Other Real Prevention, LLC trials
Trials by the same sponsor.
- NCT03932097 — REAL Parenting Alcohol and Substance Use App · NA · completed
- NCT04589676 — Developing and Testing the Opioid Rapid Response System · NA · completed
- NCT05209191 — Reducing High School Athletes' Prescription Opioids Misuse and Diversion Through the Student Athlete Wellness Portal · NA · completed
- NCT03491865 — Peer-to-peer Tobacco and ENDS Prevention · NA · withdrawn
- NCT03157700 — Interactive Technology for Media Literacy Drug Prevention in Community Groups · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03497936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Real Prevention, LLC
- Last refreshed: 19 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03497936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing